Perrigo Company announced that the FDA has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee, or NDAC, and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee, or ORUDAC, for May 9 & 10, to review the Company’s application for Opill daily oral contraceptive for over-the-counter, or OTC, use. Perrigo announced in July 2022 that its HRA Pharma affiliate filed an application with the FDA for the Rx-to-OTC switch of Opill, a progestin-only daily birth control pill.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRGO: